STAMFORD, Conn., Nov. 21, 2017 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, will exhibit the ASPIRE Cristalle Digital Mammography System with Digital Breast Tomosynthesis (DBT) at its booth (#4111, South Hall) at McCormick Place in Chicago during the 103rd scientific assembly and annual meeting of the Radiological Society of North America (RSNA).
"As an increasing number of healthcare providers have a heightened focus on patient safety and experience, Fujifilm will continue to innovate to be the ideal technology partner," said Johann Fernando, Ph.D., Chief Operating Officer of FUJIFILM Medical Systems U.S.A., Inc. "At premier radiology events such as RSNA, Fujifilm will showcase its newest solutions that includes advanced features for women's imaging such as high sensitivity capture technologies, image processing, patient comfort features, along with benefits such as superior diagnostic accuracy and reduced recall rates, all to improve patient care."
The ASPIRE Cristalle with DBT option combines state-of-the-art, Hexagonal Close Pattern (HCP) image capture technology and intelligent image processing, optimizing contrast and dose based on auto recognition of breast characteristics. It is designed to optimize image acquisition, regardless of breast composition, at a low dose. The mammography system from Fujifilm helps deliver noticeable patient comfort with its patented, flexible Comfort Paddle to provide gentle, even compression of the breast.
For even further enhanced imaging excellence, Fujifilm is offering its Dynamic Visualization II for Mammography (DVIIm) image processing software with the ASPIRE Cristalle (FFDM). The second generation offers intelligent auto recognition of breast tissue, implant and structural characteristics to intelligently adapt image contrast and density, for enhanced diagnostic visibility. DVIIm provides improved contrast and density stability throughout the entire exposure region and achieves improved visibility across a wide range of breast compositions including the presence of implants.
In addition to exhibiting its latest technology in women's health, Fujifilm will enhance the educational experience for RSNA attendees with a complimentary symposium, Innovations in Mammography for Improved Patient Care. The event will convene U.S. healthcare experts for an evening of networking and discussion along with a distinguished panel of global opinion leaders in women's health to explore the latest strategies and technologies in the use of digital breast tomosynthesis in the fight against breast cancer.
Join the following speakers on November 27, 6:30-9:00 p.m. at the Chicago Museum of History:
Complimentary registration for the Innovations in Mammography for Improved Patient Care symposium is here: http://rsna.fujimed.com/dbtsymposium
For more information about Fujifilm or to schedule a product demonstration, please visit: http://rsna.fujimed.com
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital X-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women's health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. TeraMedica Division delivers healthcare informatics, and is the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit www.fujimed.com and www.fujifilmendoscopy.com.
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2017, the company had global revenues of $20.7 billion, at an exchange rate of 112 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.